市場調査レポート
商品コード
1462316
VAC 18193の市場規模、予測、新薬の考察(2032年)VAC 18193 Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
VAC 18193の市場規模、予測、新薬の考察(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
VAC 18193はJanssenの試験中の予防RSVシニアワクチンであり、60歳以上の成人におけるRSVを介した下気道疾患の予防を目的として研究されています。この予防RSVシニアワクチン候補は、Janssenのアデノベクタープラットフォーム(AdVac)のユニークな特徴を活用しています。この試験中のワクチンには、RSVウイルスの融合タンパク質をコードする遺伝子が抗原として含まれています。
Janssenは、成人のRSV患者を対象として、2022年に米国と欧州で承認申請を行う予定です。
当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)における呼吸器合胞体ウイルス(RSV)向けVAC 18193について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"VAC 18193 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the VAC 18193 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VAC 18193 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAC 18193 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
VAC 18193 is Janssen's investigational prophylactic RSV senior vaccine, which is being investigated to prevent RSV-mediated lower respiratory tract disease in adults aged 60 or older. The prophylactic RSV senior vaccine candidate leverages unique features of Janssen's adenovector platform (AdVac). The investigational vaccine contains the gene encoding for the fusion protein of the RSV virus as an antigen.
The Company has planned submissions in US and Europe in 2022 for RSV in adult's patients.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VAC 18193 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of VAC 18193 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.